2. Search Result
Search Result
Pathways Recommended: Protein Tyrosine Kinase/RTK
Results for "

Tyrosine kinase inhibitor (Standard)

" in MedChemExpress (MCE) Product Catalog:

91

Inhibitors & Agonists

7

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50896R
    Erlotinib (Standard)

    CP-358774 (Standard); NSC 718781 (Standard); OSI-774 (Standard)

    		 Reference Standards EGFR Autophagy Cancer
    Erlotinib (Standard) is the analytical standard of Erlotinib. This product is intended for research and analytical applications. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Erlotinib (Standard)
  • HY-14596R
    Genistein (Standard)
    85+ Cited Publications

    NPI 031L (Standard)

    		 Reference Standards EGFR Autophagy Apoptosis Endogenous Metabolite Cancer
    Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
    Genistein (Standard)
  • HY-10981R
    Lenvatinib (Standard)

    E7080 (Standard)

    		 Reference Standards VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
    Lenvatinib (Standard)
  • HY-10255R
    Sunitinib Malate (Standard)

    SU 11248 Malate (Standard)

    		 Reference Standards PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib (Malate) (Standard) is the analytical standard of Sunitinib (Malate). This product is intended for research and analytical applications. Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
    Sunitinib Malate (Standard)
  • HY-50895R
    Gefitinib (Standard)

    ZD1839 (Standard)

    		 Reference Standards EGFR Autophagy Apoptosis Cancer
    Gefitinib (Standard) is the analytical standard of Gefitinib. This product is intended for research and analytical applications. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
    Gefitinib (Standard)
  • HY-101474AR
    Zanubrutinib (Standard)

    BGB-3111 (Standard)

    		 Reference Standards Btk Cancer
    Zanubrutinib (Standard) is the analytical standard of Zanubrutinib. This product is intended for research and analytical applications. Zanubrutinib (BGB-3111) is a selective and orally active Bruton tyrosine kinase (Btk) inhibitor (IC50: 0.3 nM) .
    Zanubrutinib (Standard)
  • HY-N0737AR
    Harmine (Standard)

    Telepathine (Standard)

    		 Reference Standards DYRK 5-HT Receptor Neurological Disease Cancer
    Harmine (Standard) is the analytical standard of Harmine. This product is intended for research and analytical applications. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM .
    Harmine (Standard)
  • HY-15424R
    5-Iodotubercidin (Standard)

    NSC 113939 (Standard); 5-ITu (Standard)

    		 Adenosine Kinase Reference Standards Cancer
    5-Iodotubercidin (Standard) is the analytical standard of 5-Iodotubercidin. This product is intended for research and analytical applications. 5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
    5-Iodotubercidin (Standard)
  • HY-15463R
    Imatinib (Standard)

    STI571 (Standard); CGP-57148B (Standard)

    		 Reference Standards Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy Cancer
    Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
    Imatinib (Standard)
  • HY-13223R
    Crenolanib (Standard)

    CP-868596 (Standard)

    		 FLT3 PDGFR Autophagy Reference Standards Cancer
    Crenolanib (Standard) is the analytical standard of Crenolanib. This product is intended for research and analytical applications. Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
    Crenolanib (Standard)
  • HY-N6856R
    4-Hydroxycoumarin (Standard)

    		Reference Standards Bacterial Endogenous Metabolite Infection Cancer
    4-Hydroxycoumarin (Standard) is the analytical standard of 4-Hydroxycoumarin. This product is intended for research and analytical applications. 4-Hydroxycoumarin is an orally active coumarin derivative, one of the most versatile heterocyclic scaffolds, often used in the synthesis of various organic compounds. 4-Hydroxycoumarin possesses both electrophilic and nucleophilic properties. 4-Hydroxycoumarin is an HIV protease inhibitor and tyrosine kinase inhibitor. 4-Hydroxycoumarin has anti-inflammatory, antibacterial and anti-tumor effects .
    4-Hydroxycoumarin (Standard)
  • HY-10159R
    Nilotinib (Standard)

    AMN107 (Standard)

    		 Reference Standards Bcr-Abl Autophagy Cancer
    Nilotinib (Standard) is the analytical standard of Nilotinib. This product is intended for research and analytical applications. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
    Nilotinib (Standard)
  • HY-N0198R
    Nordihydroguaiaretic acid (Standard)

    NDGA (Standard)

    		 Reference Standards Lipoxygenase Autophagy Ferroptosis Neurological Disease Cancer
    Nordihydroguaiaretic acid (Standard) is the analytical standard of Nordihydroguaiaretic acid. This product is intended for research and analytical applications. Nordihydroguaiaretic acid is a 5-lipoxygenase (5LOX) (IC50=8 μM) and tyrosine kinase inhibitor.
    Nordihydroguaiaretic acid (Standard)
  • HY-50751R
    Linifanib (Standard)

    ABT-869 (Standard); AL-39324 (Standard)

    		 PDGFR VEGFR FLT3 c-Fms c-Kit Autophagy Apoptosis Reference Standards Cancer
    Linifanib (Standard) is the analytical standard of Linifanib. This product is intended for research and analytical applications. Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .
    Linifanib (Standard)
  • HY-50905R
    Dovitinib (Standard)

    CHIR-258 (Standard); TKI258 (Standard)

    		 FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Reference Standards Cancer
    Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
    Dovitinib (Standard)
  • HY-50946R
    Imatinib Mesylate (Standard)

    STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)

    		 Reference Standards c-Kit Bcr-Abl PDGFR Autophagy Cancer
    Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
    Imatinib Mesylate (Standard)
  • HY-10338R
    Foretinib (Standard)

    XL880 (Standard); GSK1363089 (Standard); GSK089 (Standard); EXEL-2880 (Standard)

    		 Reference Standards VEGFR c-Met/HGFR Cancer
    Foretinib (Standard) is the analytical standard of Foretinib. This product is intended for research and analytical applications. Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
    Foretinib (Standard)
  • HY-10260R
    Vandetanib (Standard)

    ZD6474 (Standard)

    		 Reference Standards VEGFR Autophagy Apoptosis Cancer
    Vandetanib (Standard) is the analytical standard of Vandetanib. This product is intended for research and analytical applications. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
    Vandetanib (Standard)
  • HY-14435R
    Pyridone 6 (Standard)

    		JAK Reference Standards Cancer
    Pyridone 6 (Standard) is the analytical standard of Pyridone 6. This product is intended for research and analytical applications. Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC50s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.
    Pyridone 6 (Standard)
  • HY-10981AR
    Lenvatinib mesylate (Standard)

    E7080 mesylate (Standard)

    		 Reference Standards VEGFR FGFR PDGFR RET c-Kit Cancer
    Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
    Lenvatinib mesylate (Standard)
  • HY-101957R
    AG 1295 (Standard)

    		Reference Standards PDGFR Cardiovascular Disease
    AG 1295 (Standard) is the analytical standard of AG 1295. This product is intended for research and analytical applications. AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .
    AG 1295 (Standard)
  • HY-10065R
    Axitinib (Standard)

    AG-013736 (Standard)

    		 Reference Standards VEGFR PDGFR Cancer
    Axitinib (Standard) is the analytical standard of Axitinib. This product is intended for research and analytical applications. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
    Axitinib (Standard)
  • HY-10255AR
    Sunitinib (Standard)

    SU 11248 (Standard)

    		 Reference Standards VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib (Standard) is the analytical standard of Sunitinib. This product is intended for research and analytical applications. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
    Sunitinib (Standard)
  • HY-10205R
    Cediranib (Standard)

    AZD2171 (Standard)

    		 Reference Standards VEGFR Autophagy PDGFR Cancer
    Cediranib (Standard) is the analytical standard of Cediranib. This product is intended for research and analytical applications. Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
    Cediranib (Standard)
  • HY-15511R
    Tyrphostin A9 (Standard)

    Tyrphostin 9 (Standard); Malonoben (Standard)

    		 VEGFR Influenza Virus PDGFR Reference Standards Infection Cancer
    Tyrphostin A9 (Standard) is the analytical standard of Tyrphostin A9. This product is intended for research and analytical applications. Tyrphostin A9, a PDGFR inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has anti-influenza virus activities.
    Tyrphostin A9 (Standard)
  • HY-15656R
    Ceritinib (Standard)

    LDK378 (Standard)

    		 Reference Standards Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R Metabolic Disease Inflammation/Immunology Cancer
    Ceritinib (Standard) is the analytical standard of Ceritinib (HY-15656). This product is intended for research and analytical applications. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .
    Ceritinib (Standard)
  • HY-50895AR
    Gefitinib hydrochloride (Standard)

    ZD-1839 hydrochloride (Standard)

    		 EGFR Reference Standards Cancer
    Gefitinib (hydrochloride) (Standard) is the analytical standard of Gefitinib (hydrochloride). This product is intended for research and analytical applications. Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib hydrochloride also induces autophagy. Gefitinib hydrochloride has antitumour activity .
    Gefitinib hydrochloride (Standard)
  • HY-10207R
    Dovitinib lactate (Standard)

    CHIR-258 lactate (Standard); TKI-258 lactate (Standard)

    		 Reference Standards FLT3 c-Kit FGFR VEGFR PDGFR Cancer
    Dovitinib (lactate) (Standard) is the analytical standard of Dovitinib (lactate). This product is intended for research and analytical applications. Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively .
    Dovitinib lactate (Standard)
  • HY-10206R
    Amuvatinib (Standard)

    MP470 (Standard); HPK 56 (Standard)

    		 Reference Standards c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis Cancer
    Amuvatinib (Standard) is the analytical standard of Amuvatinib. This product is intended for research and analytical applications. Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .
    Amuvatinib (Standard)
  • HY-10331R
    Regorafenib (Standard)

    BAY 73-4506 (Standard)

    		 Reference Standards VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    Regorafenib (Standard)
  • HY-10331AR
    Regorafenib monohydrate (Standard)

    BAY 73-4506 monohydrate (Standard)

    		 Reference Standards VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate (Standard)
  • HY-16558R
    Butein (Standard)

    2’,3,4,4’-tetrahydroxy Chalcone (Standard)

    		 Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE) Cancer
    Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).
    Butein (Standard)
  • HY-10421R
    Tyrosine kinase inhibitor (Standard)

    		Reference Standards c-Met/HGFR Cancer
    Tyrosine kinase inhibitor (Standard) is the analytical standard of Tyrosine kinase inhibitor (HY-10421). This product is intended for research and analytical applications. Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
    Tyrosine kinase inhibitor (Standard)
  • HY-117718R
    AG957 (Standard)

    Tyrphostin AG957 (Standard); NSC 654705 (Standard)

    		 Bcr-Abl Reference Standards Cancer
    AG957 (Standard) is the analytical standard of AG957. This product is intended for research and analytical applications. AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity .
    AG957 (Standard)
  • HY-101820R
    Simotinib (Standard)

    		Reference Standards EGFR Cancer
    Simotinib (Standard) is the analytical standard of Simotinib. This product is intended for research and analytical applications. Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities .
    Simotinib (Standard)
  • HY-18963R
    Lavendustin A (Standard)

    RG-14355 (Standard)

    		 Reference Standards EGFR Cancer
    Lavendustin A (Standard) is the analytical standard of Lavendustin A. This product is intended for research and analytical applications. Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis[1][2].
    Lavendustin A (Standard)
  • HY-10322R
    Falnidamol (Standard)

    BIBX 1382 (Standard)

    		 Reference Standards EGFR Cancer
    Falnidamol (Standard) is the analytical standard of Falnidamol. This product is intended for research and analytical applications. Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity .
    Falnidamol (Standard)
  • HY-10159AR
    Nilotinib monohydrochloride monohydrate (Standard)

    AMN107 monohydrochloride monohydrate (Standard)

    		 Reference Standards Bcr-Abl Autophagy Cancer
    Nilotinib (monohydrochloride monohydrate) (Standard) is the analytical standard of Nilotinib (monohydrochloride monohydrate). This product is intended for research and analytical applications. Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
    Nilotinib monohydrochloride monohydrate (Standard)
  • HY-12297R
    Sulfatinib (Standard)

    Surufatinib (Standard); HMPL-012 (Standard)

    		 Reference Standards FGFR VEGFR Cancer
    Sulfatinib (Standard) is the analytical standard of Sulfatinib. This product is intended for research and analytical applications. Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.
    Sulfatinib (Standard)
  • HY-13802R
    SC-514 (Standard)

    GK 01140 (Standard)

    		 IKK Reference Standards Cancer
    SC-514 (Standard) is the analytical standard of SC-514. This product is intended for research and analytical applications. SC-514 is a selective IKK-2 inhibitor (IC50=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.
    SC-514 (Standard)
  • HY-108330R
    AG126 (Standard)

    Tyrphostin AG126 (Standard)

    		 ERK Mitosis Reference Standards Inflammation/Immunology
    AG126 (Standard) is the analytical standard of AG126. This product is intended for research and analytical applications. AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of ERK1 and ERK2 at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research .
    AG126 (Standard)
  • HY-50898R
    Lapatinib (Standard)

    GW572016 (Standard); GW2016 (Standard)

    		 Reference Standards EGFR Autophagy Ferroptosis Cancer
    Lapatinib (Standard) is the analytical standard of Lapatinib. This product is intended for research and analytical applications. Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib (Standard)
  • HY-10234AR
    Saracatinib difumarate (Standard)

    AZD0530 difumarate (Standard)

    		 Src Reference Standards Cancer
    Saracatinib (difumarate) (Standard) is the analytical standard of Saracatinib (difumarate). This product is intended for research and analytical applications. Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
    Saracatinib difumarate (Standard)
  • HY-13524R
    AG-1478 (Standard)

    Tyrphostin AG-1478 (Standard); NSC 693255 (Standard)

    		 EGFR HCV Influenza Virus Reference Standards Infection Cardiovascular Disease Metabolic Disease Cancer
    AG-1478 (Standard) is the analytical standard of AG-1478. This product is intended for research and analytical applications. AG-1478 (Tyrphostin AG-1478) is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. AG-1478 has antiviral effects against HCV and encephalomyocarditis virus (EMCV).
    AG-1478 (Standard)
  • HY-10234R
    Saracatinib (Standard)

    AZD0530 (Standard)

    		 Reference Standards Src Autophagy Cancer
    Saracatinib (Standard) is the analytical standard of Saracatinib. This product is intended for research and analytical applications. Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .
    Saracatinib (Standard)
  • HY-101958R
    Tyrphostin 25 (Standard)

    AG82 (Standard); Tyrphostin A 25 (Standard); Tyrphostin AG 82 (Standard); RG-50875 (Standard)

    		 Reference Standards EGFR GPR35 Inflammation/Immunology Cancer
    Tyrphostin 25 (Standard) (AG82 (Standard)) is the analytical standard of Tyrphostin 25 (HY-101958). This product is intended for research and analytical applications. Tyrphostin 25 (AG82) is a specific inhibitor of the EGFR tyrosine kinase with an IC50 value of 3 µM in A431 cells. Tyrphostin 25 is also a GPR35 agonist with an EC50 of 5.3 µM .
    Tyrphostin 25 (Standard)
  • HY-50898BR
    Lapatinib ditosylate monohydrate (Standard)

    GW572016 ditosylate monohydrate (Standard); GW2016 ditosylate monohydrate (Standard)

    		 EGFR Autophagy Ferroptosis Reference Standards Cancer
    Lapatinib (ditosylate monohydrate) (Standard) is the analytical standard of Lapatinib (ditosylate monohydrate). This product is intended for research and analytical applications. Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib ditosylate monohydrate (Standard)
  • HY-50898AR
    Lapatinib ditosylate (Standard)

    GW572016 ditosylate (Standard); GW2016 ditosylate (Standard)

    		 EGFR Autophagy Ferroptosis Reference Standards Cancer
    Lapatinib (ditosylate) (Standard) is the analytical standard of Lapatinib (ditosylate). This product is intended for research and analytical applications. Lapatinib ditosylate (GW572016 ditosylate) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
    Lapatinib ditosylate (Standard)
  • HY-12044R
    Cabozantinib S-malate (Standard)

    XL184 S-malate (Standard); BMS-907351 S-malate (Standard)

    		 Reference Standards VEGFR Apoptosis Cancer
    Cabozantinib (S-malate) (Standard) is the analytical standard of Cabozantinib (S-malate). This product is intended for research and analytical applications. Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Cabozantinib S-malate (Standard)
  • HY-100833R
    Antibiotic-5d (Standard)

    		Reference Standards Bacterial Antibiotic Infection
    Cabozantinib (S-malate) (Standard) is the analytical standard of Cabozantinib (S-malate). This product is intended for research and analytical applications. Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Antibiotic-5d (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: